SIStockInvestingSI.com

NYSE · COR · Medical Distribution

Cencora, Inc. (COR) stock analysis

$340.43−0.83%Data as of Oct 21, 2026
  • COR gained 8.3% over the past month versus 0.0% for the S&P 500, ranking 87th of 497 S&P 500 stocks.
  • Over 12 months it returned +4.3%, 11.5 points behind the S&P 500, and trades 9.0% below its 52-week high.
  • In the last 30 days 3 analysts raised earnings estimates and 5 cut; forward EPS moved −0.1% (−0.1% over 90 days).
  • It sits in the Drug distribution segment of the Healthcare Value Chain, where the 1-month median return is +13.9%.
  • The daily chart reads Trend transition · Upside breakout (since Oct 21, 2026).
Market cap$65.0B
12-month return+4.3%
Forward P/E17.2×
Mean target vs price+8.4%

One-year price with 50- and 200-day averages

Open in Hub
263297331365JanAprJulOct
340.4350-day200-day

Performance vs the market

Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.

COR+8.3%
Sector median−8.7%
S&P 5000.0%
COR+11.6%
Sector median−5.4%
S&P 500+4.7%
COR+10.4%
Sector median−1.5%
S&P 500+8.7%
COR+4.3%
Sector median+1.7%
S&P 500+15.8%
1-month rank in the S&P 50087 / 497
3-month rank in its sector · Healthcare201 / 720

Chart structure

Read by our daily-bar structure engine from swing highs, swing lows and moving averages.

Trend transition · Upside breakoutConfirmed

Holding since Oct 21, 2026

  • Close above EMA20 above EMA50
  • EMA50 rose over the last ten sessions
  • Confirmed swing highs and lows are rising
  • Intermediate and long-term directions differ
This pattern on this stock

91 occurrences in 10 years. The median move over the next 20 sessions was +2.1%, positive 57% of the time, against +1.6% for any day in the same period.

Reference zone, stop and targets for this structureSee the trade plan in Hub ↗

Analyst earnings revisions

Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.

Forward EPS$19.80
30-day change−0.1%
90-day change−0.1%
Mean target$369.08 +8.4%
Raised (30d) 3Cut (30d) 5

12 analysts cover the stock

Fundamental shape vs peers

Six dimensions on fixed scales. The filled shape is the company; the outline is the peer average.

Open the full Radar with every ratio
ValuationRevisionsMomentumGrowthCashProfit

Ahead of peersValuation

PeersMCK · CAH · HSIC

Where it sits in the supply chain

Healthcare Value Chain · Distribution & PBMs

Explore the full chain map in Hub
Supplied by
Obesity & metabolic (GLP-1)+3.8%
LLY+8.6%1 monthNVO−0.9%1 month
Large pharma−0.7%
JNJ−4.2%1 monthMRK−0.7%1 monthABBV+7.4%1 monthPFE+6.9%1 monthBMY−0.8%1 month
Biotech+0.4%
AMGN+6.8%1 monthREGN+0.2%1 monthGILD+0.6%1 monthVRTX+1.9%1 monthALNY−10.6%1 monthMRNA+34.6%1 monthBIIB+6.9%1 monthINSM−22.2%1 monthINCY−10.6%1 monthCATX−22.3%1 month
Generics & established medicines+7.4%
VTRS+7.4%1 month
Its segment
Drug distribution+13.9%
MCK+13.9%1 monthCOR+8.3%1 monthCAH+16.2%1 month

Three distributors handle most US prescription drug flow; revenue grows with prescription volume and high-priced specialty drugs, including GLP-1s.

Sells into
PBMs & pharmacies+9.3%
CVS+7.3%1 monthCI+11.2%1 monthUNH+11.8%1 month6618.HK+7.3%1 month
Hospitals & care delivery+8.4%
HCA+4.9%1 monthUNH+11.8%1 month

Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps

Risk profile

Max drawdown, 12M−32.6%
Volatility, 60D25.9%
From 52-week high−9.0%
From 52-week low+35.0%
Trailing P/E25.3×
Forward P/E17.2×
MCKMcKessonCAHCardinal Health, Inc.LLYEli LillyJNJJohnson & JohnsonMRKMerckABBVAbbViePFEPfizerBMYBristol Myers Squibb

Track this stock every day

Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.

Open in Hub ↗